(lp0
S"Ionis Exonerated, Buying Opportunity Created By Goldman Downgrade Seeking Alpha - Mar 13, 2017 Long-term investors should stiff-arm today's Goldman Sachs downgrade of Ionis Pharmaceuticals  from Neutral to Sell because analyst Salveen Richter has ignored recent evidence exonerating the platform of alleged toxicity."
p1
aS"Ionis' Latest Attempt To Weaponize Antisense Against Cancer Seeking Alpha - 19 hours ago Cancer-causing mutations in the KRAS gene have been studied for 30 years yet no direct inhibitor of mutant KRAS enzyme has entered clinical trials.Ionis Pharmaceuticals Inc  Downgraded by Goldman Sachs Group Inc - BNB Daily The Ionis Pharmaceuticals Inc  Price Target Cut to $59.00 - Petro Global News 24"
p2
aS'Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen ... PR Newswire  - Mar 6, 2017 CARLSBAD, Calif. and CAMBRIDGE, Mass., March 6, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. , today announced that the pivotal Phase 3 APPROACH study of volanesorsen met its&nbsp;...Why Ionis Pharmaceuticals Rallied 12% in February - Motley Fool'
p3
aS'Why Ionis Pharmaceuticals Is Tumbling 10% Today Motley Fool - Mar 10, 2017 What happened. After highly regarded investment firm Goldman Sachs cut its rating on the company, Ionis Pharmaceuticals  shares dropped by more than 10% at 1:45 p.m. EST today.Ionis Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 10 - Equities.com'
p4
aS"Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money Motley Fool - Mar 1, 2017 Ionis Pharmaceuticals  reported fourth-quarter earnings on Tuesday. The biotech has two drugs on the market, but given Kynamro's low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December, most of&nbsp;..."
p5
aS'Stock Update : Ionis Pharmaceuticals Inc Earns $75 Million from ... Smarter Analyst - Feb 14, 2017 Ionis Pharmaceuticals, Inc.  announced the advancement of IONIS-FXIRx in clinical development under an existing exclusive license agreement with Bayer.Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx - PR Newswire Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call - Yahoo Finance'
p6
aS"Company Update : Here's Why Ionis Pharmaceuticals Inc Shares ... Smarter Analyst - Feb 28, 2017 Ionis Pharmaceuticals Inc  reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments.Ionis Pharmaceuticals  Beats on Q4 Earnings - Yahoo FinanceIonis' 2016 Financial Results Outperform Financial Guidance - PR Newswire "
p7
aS'Ionis Pharma Lipid Disorder Candidate Positive in Phase III Yahoo Finance - Mar 8, 2017 Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. IONS, recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome .'
p8
aS'SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ionis ... Yahoo Finance - Mar 8, 2017 Ionis reported 8 serious adverse events concerned with volanesorsen. If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.'
p9
aS'Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical ... PR Newswire  - Feb 16, 2017 CARLSBAD, Calif. and CAMBRIDGE, Mass., Feb. 16, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.  and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced today they have closed on their exclusive&nbsp;...'
p10
a.